IP Verse

Adjuvant Treatment Of Her2-Positive Breast Cancer

Patent No. EP3589661 (titled "Adjuvant Treatment Of Her2-Positive Breast Cancer") was filed by F Hoffmann LA Roche on Feb 28, 2018. The application was issued on Nov 1, 2023.

Patent Summary

Combination therapy for HER2-positive breast cancer that extends survival compared to trastuzumab alone. The treatment combines pertuzumab with trastuzumab and chemotherapy, administered after breast surgery. The combination provides enhanced anti-tumor activity against HER2-positive breast cancer while addressing potential resistance mechanisms.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MICHALSKI HTTERAMNN & PARTNERAug 1, 2024-
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBAug 1, 2024-
ABEL & IMRAYJul 31, 2024-
LANYON OPPOSITIONSJul 31, 2024PINSENT MASONS
BRAND MURRAY FULLERJul 23, 2024BRAND MURRAY FULLER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3589661

F HOFFMANN LA ROCHE
Application Number
EP18712044A
Filing Date
Feb 28, 2018
Status
Granted And Under Opposition
Sep 29, 2023
Publication Date
Nov 1, 2023
External Links
Slate, Register , Google Patents